Latest news with #ArtivaBiotherapeutics
Globe and Mail
a day ago
- Business
- Globe and Mail
Non-Hodgkin Lymphoma Pipeline Appears Robust With 180+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Non-Hodgkin Lymphoma Pipeline Insight, 2025 ' report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Non-Hodgkin Lymphoma pipeline landscape. It covers the Non-Hodgkin Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Hodgkin Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Non-Hodgkin Lymphoma Treatment Landscape. Click here to read more @ Non-Hodgkin Lymphoma Pipeline Outlook Key Takeaways from the Non-Hodgkin Lymphoma Pipeline Report In June 2025, AstraZeneca announced a study is designed to evaluate the safety, tolerability, PK, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies. In June 2025, Genmab conducted a study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed. In June 2025, Artiva Biotherapeutics Inc. organized clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or in combination with rituximab (including the DLBCL specific cohort) or in combination with bendamustine and rituximab; 2) to evaluate the potential clinical activity of AB-101 when given in combination with rituximab or in combination with bendamustine and rituximab (combination cohorts only); and 3) to identify the recommended Phase 2 dose (RP2D). The primary objective of Phase 2 is to determine whether AB-101 in combination with rituximab or in combination with bendamustine and rituximab has anti-cancer activity in patients. DelveInsight's Non-Hodgkin Lymphoma pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Non-Hodgkin Lymphoma treatment. The leading Non-Hodgkin Lymphoma Companies such as Bristol Mayer Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA and others. Promising Non-Hodgkin Lymphoma Pipeline Therapies such as Bendamustine hydrochloride injection, Glofitamab, Atezolizumab, Obinutuzumab, Lenalidomide, Velcade, Temsirolimus, PF-3512676 and others. Discover groundbreaking developments in Non-Hodgkin Lymphoma Therapies! Gain in-depth knowledge of key Non-Hodgkin Lymphoma clinical trials, emerging drugs, and market opportunities @ Non-Hodgkin Lymphoma Clinical Trials Assessment Non-Hodgkin Lymphoma Emerging Drugs Profile Golcadomide: Bristol Myers Squibb Golcadomide is a novel cereblon E3 ligase modulator (CELMoD) being investigated for the treatment of aggressive B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). In combination with R-CHOP chemotherapy, it has shown promising antitumor activity in high-risk DLBCL patients, with a high overall response rate (ORR) and complete metabolic response (CMR). Currently, the drug is in Phase III stage of its clinical trial for the treatment of Non-Hodgkin Lymphoma. MEN 1703: Ryvu Therapeutics MEN1703 (SEL24) is a clinical-stage program discovered and developed by Ryvu Therapeutics and licensed to the Menarini Group. MEN1703 is a first-in-class, dual PIM/FLT3 kinase inhibitor with a unique activity profile. By design, this profile may provide responses to treatment that are more durable than current options and address a disease that has progressed following FLT3 inhibition. Preclinical data suggests therapeutic potential in both hematological malignancies and in solid tumors. Ryvu has granted the Menarini Group an exclusive worldwide license to further research, develop, manufacture and commercialize MEN1703 (SEL24). Currently the drug is in Phase II stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma. LP-168: Guangzhou Lupeng Pharmaceutical LP-168 is a third-generation, orally active, irreversible EGFR tyrosine kinase inhibitor (TKI) developed by Guangzhou Lupeng Pharmaceutical for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, including T790M resistance mutations. It is designed to target mutant EGFR while sparing wild-type EGFR, potentially reducing side effects. LP-168 has shown promising preclinical activity and is currently in clinical trials. The company is exploring its use in both first-line and resistant EGFR-mutant NSCLC settings. Currently the drug is in Phase II stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma. DR-0201: Dren Bio DR-0201 is an investigational drug developed by D.R. Pharmatech, designed as a novel anti-cancer agent targeting HER2-expressing tumors, particularly in gastric and breast cancers. It is a HER2-targeting antibody-drug conjugate (ADC) that combines a monoclonal antibody with a cytotoxic payload to selectively kill cancer cells while minimizing damage to healthy tissue. DR-0201 aims to overcome resistance seen with existing HER2 therapies. The product is currently undergoing preclinical or early-phase clinical evaluation. Currently the drug is in Phase I stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma. ETR-7072 is an investigational small-molecule drug developed by EntreChem, designed to target cancer by modulating transcriptional programs involved in tumor growth and survival. It is part of EntreChem's novel class of natural product-inspired compounds with multi-targeted activity, potentially affecting epigenetic regulators and oncogenic pathways. ETR-7072 shows promise in preclinical models for treating aggressive and resistant cancers. The compound is currently in early-stage development, with ongoing studies to assess its safety and efficacy. Currently the drug is in Preclinical stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma. The Non-Hodgkin Lymphoma Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Non-Hodgkin Lymphoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Hodgkin Lymphoma Treatment. Non-Hodgkin Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Non-Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Hodgkin Lymphoma market Stay informed about the Non-Hodgkin Lymphoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Non-Hodgkin Lymphoma Unmet Needs Non-Hodgkin Lymphoma Companies Bristol Mayer Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA and others. Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as Monoclonal antibody Small molecule Peptide Transform your understanding of the Non-Hodgkin Lymphoma Pipeline! See the latest progress in drug development and clinical research @ Non-Hodgkin Lymphoma Market Drivers and Barriers, and Future Perspectives Scope of the Non-Hodgkin Lymphoma Pipeline Report Coverage- Global Non-Hodgkin Lymphoma Companies- Bristol Mayer Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA and others. Non-Hodgkin Lymphoma Pipeline Therapies- Bendamustine hydrochloride injection, Glofitamab, Atezolizumab, Obinutuzumab, Lenalidomide, Velcade, Temsirolimus, PF-3512676 and others. Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Stay Ahead in Research-Access the Full Non-Hodgkin Lymphoma Pipeline Analysis Today! @ Non-Hodgkin Lymphoma Drugs and Companies Table of Contents Introduction Executive Summary Non-Hodgkin Lymphoma: Overview Pipeline Therapeutics Therapeutic Assessment Non-Hodgkin Lymphoma– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Golcadomide: Bristol Myers Squibb Mid Stage Products (Phase II) MEN 1703: Ryvu Therapeutics Early Stage Products (Phase I) DR-0201: Dren Bio Preclinical and Discovery Stage Products ETR-7072: EntreChem Inactive Products Non-Hodgkin Lymphoma Key Companies Non-Hodgkin Lymphoma Key Products Non-Hodgkin Lymphoma- Unmet Needs Non-Hodgkin Lymphoma- Market Drivers and Barriers Non-Hodgkin Lymphoma- Future Perspectives and Conclusion Non-Hodgkin Lymphoma Analyst Views Non-Hodgkin Lymphoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
3 days ago
- Business
- Yahoo
Will Artiva Biotherapeutics (NASDAQ:ARTV) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed. So should Artiva Biotherapeutics (NASDAQ:ARTV) shareholders be worried about its cash burn? For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). First, we'll determine its cash runway by comparing its cash burn with its cash reserves. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. In March 2025, Artiva Biotherapeutics had US$166m in cash, and was debt-free. In the last year, its cash burn was US$61m. So it had a cash runway of about 2.7 years from March 2025. That's decent, giving the company a couple years to develop its business. The image below shows how its cash balance has been changing over the last few years. See our latest analysis for Artiva Biotherapeutics Because Artiva Biotherapeutics isn't currently generating revenue, we consider it an early-stage business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Over the last year its cash burn actually increased by 23%, which suggests that management are increasing investment in future growth, but not too quickly. That's not necessarily a bad thing, but investors should be mindful of the fact that will shorten the cash runway. While the past is always worth studying, it is the future that matters most of all. So you might want to take a peek at how much the company is expected to grow in the next few years. Given its cash burn trajectory, Artiva Biotherapeutics shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Commonly, a business will sell new shares in itself to raise cash and drive growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate). Since it has a market capitalisation of US$36m, Artiva Biotherapeutics' US$61m in cash burn equates to about 170% of its market value. That suggests the company may have some funding difficulties, and we'd be very wary of the stock. Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought Artiva Biotherapeutics' cash runway was relatively promising. Even though we don't think it has a problem with its cash burn, the analysis we've done in this article does suggest that shareholders should give some careful thought to the potential cost of raising more money in the future. On another note, Artiva Biotherapeutics has 5 warning signs (and 3 which are potentially serious) we think you should know about. If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow. — Investing narratives with Fair Values A case for TSXV:USA to reach USD $5.00 - $9.00 (CAD $7.30–$12.29) by 2029. By Agricola – Community Contributor Fair Value Estimated: CA$12.29 · 0.9% Overvalued DLocal's Future Growth Fueled by 35% Revenue and Profit Margin Boosts By WynnLevi – Community Contributor Fair Value Estimated: $195.39 · 0.9% Overvalued Historically Cheap, but the Margin of Safety Is Still Thin By Mandelman – Community Contributor Fair Value Estimated: SEK232.58 · 0.1% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
